Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
Curie Oncology
National Cancer Centre
National University Hospital
Trial Status: NA
Principal Investigator(s):
Dr John Chia Whay Kuang
Dr Jack Chan Junjie
Dr David Tan Shao Peng
Published by HT Digital Content Services with permission from Health Daily Digest....